Results 261 to 270 of about 5,946,067 (288)

Zoledronic-acid

Reactions Weekly, 2018
  +4 more sources

Zoledronic acid

Reactions Weekly, 2016
openaire   +2 more sources

Zoledronic acid

Reactions Weekly, 2015
  +4 more sources

Zoledronic acid

Reactions Weekly, 2014
openaire   +2 more sources

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

The Lancet Oncology, 2018
N. Raje, E. Terpos, W. Willenbacher, K. Shimizu, R. García-Sanz, B. Durie, W. Legieć, M. Krejci, K. Laribi, Li Zhu, P. Cheng, D. Warner, G. David Roodman   +12 more
semanticscholar   +1 more source

Safety and efficacy of zoledronic acid in multiple myeloma

Lancet, The, 2011
Tetsutaro Matayoshi, Kengo Takeuchi
exaly   +2 more sources

Zoledronic acid accelerates osteogenesis of bone marrow mesenchymal stem cells by attenuating oxidative stress via the SIRT3/SOD2 pathway and thus alleviates osteoporosis.

European Review for Medical and Pharmacological Sciences, 2020
Zhehu Jin, S.F. Wang, W. Liao
semanticscholar   +1 more source

Zoledronic-acid

Reactions Weekly
  +4 more sources

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Lancet, The, 2010
Faith E Davies, Kim Cocks, Mark T Drayson   +2 more
exaly  

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Lancet, The, 2011
Matthew D Smith, Janet E Brown, Lawrence I Karsh   +2 more
exaly